Compare · DRUG vs MRK
DRUG vs MRK
Side-by-side comparison of Bright Minds Biosciences Inc. (DRUG) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRUG and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $356.13B, about 1604.0x DRUG ($222.0M).
- MRK has been more active in the news (19 items in the past 4 weeks vs 6 for DRUG).
- MRK has more recent analyst coverage (25 ratings vs 9 for DRUG).
- Company
- Bright Minds Biosciences Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- $222.0M
- $356.13B
- 1M return
- -
- -0.97%
- 1Y return
- -
- +55.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 19
- Recent ratings
- 9
- 25
Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest DRUG
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- BRIGHT MINDS BIOSCIENCES DRUG INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 52.3% Share Drop
- DRUG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Bright Minds Biosciences (DRUG)
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
- Wolfe Research initiated coverage on Bright Minds Biosciences with a new price target
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Latest MRK
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)